Anika Webb, PA
Payments from drug & device makers
Across 352 payments — averaging $16.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Lilly USA, LLC$710
- ANI Pharmaceuticals, Inc.$491
- AstraZeneca$457
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$312
- Amgen$258
- plus $2K from 31 others
What the payments were for
- Food & beverage$5,748100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 73 | $1,186 |
| Lilly USA, LLC | 49 | $710 |
| ANI Pharmaceuticals, Inc. | 35 | $491 |
| AstraZeneca | 20 | $457 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $312 |
| Amgen | 16 | $258 |
| Boehringer Ingelheim | 15 | $231 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $231 |
| Novo Nordisk | 14 | $218 |
| Pfizer | 10 | $172 |
| Axsome Therapeutics, Inc. | 8 | $151 |
| Lundbeck LLC | 6 | $133 |
| Kowa Pharmaceuticals America, Inc. | 7 | $107 |
| Johnson & Johnson(2 entities) | 7 | $102 |
| Merck | 7 | $94 |
| Bayer | 6 | $93 |
| Biohaven Pharmaceuticals, Inc. | 6 | $88 |
| GSK | 5 | $73 |
| Dexcom, Inc. | 4 | $72 |
| Antares Pharma, Inc. | 3 | $56 |
| Sanofi-aventis U.S. LLC | 3 | $44 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $43 |
| Exact Sciences | 2 | $42 |
| Otsuka America Pharmaceutical, Inc. | 2 | $41 |
| Halozyme Inc | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 3 | $36 |
| Eisai Inc. | 2 | $36 |
| E.r. Squibb & Sons, L.L.C. | 2 | $36 |
| Xeris Pharmaceuticals, Inc. | 2 | $32 |
| Inspire Medical Systems, Inc. | 1 | $31 |
| Amarin Pharma, Inc. | 2 | $30 |
| Verona Pharma, Inc. | 1 | $22 |
| Ferring Pharmaceuticals Inc. | 1 | $20 |
| Organogenesis Inc. | 1 | $17 |
| Vanda Pharmaceuticals Inc. | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Novartis | 1 | $14 |
How this compares
$5,748 in reported general payments places this provider in the 90th percentile of 2,594 medical providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 46 | $43,800 |
| RexultiBrexpiprazole | 17 | $24,305 |
| JardianceEmpagliflozin | 32 | $20,185 |
| VraylarCariprazine Hcl | 14 | $19,813 |
| OxycontinOxycodone Hcl | 25 | $18,795 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $16,329 |
| EliquisApixaban | 23 | $16,298 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $14,508 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 29 | $13,542 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 14 | $12,906 |
| FarxigaDapagliflozin Propanediol | 17 | $9,544 |
| EntrestoSacubitril/Valsartan | 12 | $9,431 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $4,021 |
| Varenicline Tartrate | 14 | $3,620 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 81 | $2,922 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $218 | $43,80046 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $73 | $28,05046 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $457 | $27,99547 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $41 | $24,30517 claims |
| AbbVieVraylar, Synthroid | $1,186 | $20,88942 claims |
| Boehringer IngelheimJardiance | $231 | $20,18532 claims |
| PfizerEliquis | $172 | $16,29823 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $44 | $12,90614 claims |
| NovartisEntresto | $14 | $9,43112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,594 medical providers in Pennsylvania.
Other medical in Troy
- Jacqueline KernaghanSpringfield$427K
- Drew SodaNew Hope$220K
- Angela KapalkoPhiladelphia$123K
- Linda PerryPhiladelphia$123K
- Cory DavidsonErie$119K
- Shelley SassamanTamaqua$90K
- Meghan HoffnerBethlehem$86K
- Thomas IacovoniDanville$72K
- Scott CoxWynnewood$66K
- Sarah SmithPhiladelphia$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.